Published in Nat Immunol on November 17, 2013
Immune responses to HCV and other hepatitis viruses. Immunity (2014) 1.52
IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nat Genet (2017) 1.41
IFN-λ4: the paradoxical new member of the interferon lambda family. J Interferon Cytokine Res (2014) 1.32
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest (2014) 1.29
Interferon-λ: Immune Functions at Barrier Surfaces and Beyond. Immunity (2015) 1.16
Noncoding RNA and its associated proteins as regulatory elements of the immune system. Nat Immunol (2014) 1.15
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun (2015) 1.14
Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. J Hepatol (2015) 0.99
The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg Microbes Infect (2014) 0.96
Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4). PLoS Genet (2014) 0.92
Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden. Virology (2015) 0.89
Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study. Genes Immun (2015) 0.86
Translating the Untranslated Region. J Immunol (2015) 0.86
MicroRNAs: Role in Hepatitis C Virus pathogenesis. Genes Dis (2015) 0.85
Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types. Front Immunol (2014) 0.85
IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance. Sci Rep (2015) 0.82
Post-transcriptional regulation of interferons and their signaling pathways. J Interferon Cytokine Res (2014) 0.82
Outflanking HCV. Nat Immunol (2014) 0.82
Hepatitis C Virus. Strategies to Evade Antiviral Responses. Future Virol (2015) 0.81
Interferon lambda: opportunities, risks, and uncertainties in the fight against HCV. Front Immunol (2014) 0.80
Viral genotype correlates with distinct liver gene transcription signatures in chronic hepatitis C virus infection. Liver Int (2015) 0.80
Host-virus interactions in hepatitis B and hepatitis C infection. J Gastroenterol (2016) 0.79
Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. J Viral Hepat (2016) 0.79
Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions. J Interferon Cytokine Res (2014) 0.78
Recent advances in understanding hepatitis C. F1000Res (2016) 0.78
Organ system view of the hepatic innate immunity in HCV infection. J Med Virol (2016) 0.78
Innate and Adaptive Immune Responses in Chronic HCV infection. Curr Drug Targets (2015) 0.77
Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals. J Clin Cell Immunol (2014) 0.77
Detection of allele specific differences in IFNL3 (IL28B) mRNA expression. BMC Med Genet (2014) 0.77
Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma Risk. Sci Rep (2015) 0.77
Hepatic Interferon-λ3 (IFNL3) Gene Expression Reveals Not to Be Attenuated in Non-Favorable IFNL3 rs4803217 or IFNL4 rs368234815 Minor Allele Carriers in Chronic Hepatitis C. PLoS One (2015) 0.77
Landscape of post-transcriptional gene regulation during hepatitis C virus infection. Curr Opin Virol (2015) 0.77
Interferon lambda 4 expression is suppressed by the host during viral infection. J Exp Med (2016) 0.76
Insights into antiviral innate immunity revealed by studying hepatitis C virus. Cytokine (2015) 0.76
Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth. Oncotarget (2016) 0.76
Polymorphisms in EGFR and IL28B are associated with spontaneous clearance in an HCV-infected iranian population. Genes Immun (2015) 0.75
Influence of host resistance on viral adaptation: hepatitis C virus as a case study. Infect Drug Resist (2015) 0.75
The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy. J Immunol Res (2017) 0.75
Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C. World J Gastroenterol (2017) 0.75
IFNL3 expression and response to treatment: behind the HCV tricks. J Hepatol (2014) 0.75
Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C? World J Virol (2015) 0.75
Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. Nat Med (2016) 0.75
Long Non-coding RNAs in Hepatitis C Virus-Infected Cells. Front Microbiol (2017) 0.75
IFN-λ 'guts' neutrophil-mediated inflammation. Nat Immunol (2017) 0.75
Re-evaluating Strategies to Define the Immunoregulatory Roles of miRNAs. Trends Immunol (2017) 0.75
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature (2010) 22.04
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol (2002) 11.87
IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol (2002) 11.22
Treatment of HCV infection by targeting microRNA. N Engl J Med (2013) 9.91
ViennaRNA Package 2.0. Algorithms Mol Biol (2011) 9.43
Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol (2005) 9.11
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature (2008) 6.25
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc Natl Acad Sci U S A (2006) 5.70
Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A (2005) 5.64
Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A (2005) 5.31
A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell (2009) 5.28
B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol (2003) 4.87
IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog (2008) 4.70
Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology (2010) 4.58
MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol (2011) 4.00
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J Virol (2006) 2.57
Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun (2008) 2.40
Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature (2011) 2.36
Interferon-lambda serum levels in hepatitis C. J Hepatol (2010) 2.28
Immunoprecipitation of mRNA-protein complexes. Nat Protoc (2006) 2.21
Cell culture and infection system for hepatitis C virus. Nat Protoc (2006) 2.14
mRNA openers and closers: modulating AU-rich element-controlled mRNA stability by a molecular switch in mRNA secondary structure. Chembiochem (2004) 1.82
IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev (2010) 1.45
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology (2012) 1.43
Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis (2012) 1.40
Evolutionary genetic dissection of human interferons. J Exp Med (2011) 1.32
Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology (2011) 1.30
The role of cytokine mRNA stability in the pathogenesis of autoimmune disease. Autoimmun Rev (2005) 1.21
Interferon-lambda (IFN-λ) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. J Leukoc Biol (2012) 1.17
Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology (2012) 1.16
Potential pitfalls in microRNA profiling. Wiley Interdiscip Rev RNA (2012) 1.14
Analysis of IL28B variants in an Egyptian population defines the 20 kilobases minimal region involved in spontaneous clearance of hepatitis C virus. PLoS One (2012) 1.13
Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus. Hepatology (2013) 1.07
Uridine composition of the poly-U/UC tract of HCV RNA defines non-self recognition by RIG-I. PLoS Pathog (2012) 1.07
Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients. PLoS One (2012) 1.05
Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol (2000) 1.04
Hepatitis C virus infection and cardiomyopathies. Circ Res (2005) 1.03
Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication. Antimicrob Agents Chemother (2012) 1.01
Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity (2008) 1.00
IL28B genotype and the expression of ISGs in normal liver. Liver Int (2013) 0.99
Differences in microRNA detection levels are technology and sequence dependent. RNA (2013) 0.93
Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. Nat Med (2016) 0.75
IFN-λ 'guts' neutrophil-mediated inflammation. Nat Immunol (2017) 0.75